Latest news with #AcadiaPharmaceuticals
Yahoo
a day ago
- Business
- Yahoo
US appeals court confirms patent validity of Acadia's Parkinson's drug
(Reuters) -Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, its drug for hallucinations and delusions associated with Parkinson's disease. The decision supports a December 2023 ruling from the U.S. District Court of Delaware, ensuring the patent remains protected in Acadia's legal battle against India-based drugmaker MSN Laboratories. The appeals court followed a precedent that says an earlier patent claim cannot be invalidated by a later one if they share the same priority date. "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for Nuplazid, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for Nuplazid 34 mg capsule formulation into 2038," said CEO Catherine Owen Adams. This decision comes after another favorable ruling for Acadia regarding its formulation patent for Nuplazid. The court supported Acadia's claims of infringement and validity in its legal case against Aurobindo Pharma and other companies. The U.S. FDA approved Nuplazid for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis in 2016.
Reuters
a day ago
- Business
- Reuters
US appeals court confirms patent validity of Acadia's Parkinson's drug
June 9 (Reuters) - Acadia Pharmaceuticals (ACAD.O), opens new tab said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, its drug for hallucinations and delusions associated with Parkinson's disease. The decision supports a December 2023 ruling from the U.S. District Court of Delaware, ensuring the patent remains protected in Acadia's legal battle against India-based drugmaker MSN Laboratories. The appeals court followed a precedent that says an earlier patent claim cannot be invalidated by a later one if they share the same priority date. "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for Nuplazid, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for Nuplazid 34 mg capsule formulation into 2038," said CEO Catherine Owen Adams. This decision comes after another favorable ruling for Acadia regarding its formulation patent for Nuplazid. The court supported Acadia's claims of infringement and validity in its legal case against Aurobindo Pharma ( opens new tab and other companies. The U.S. FDA approved Nuplazid for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis in 2016.
Yahoo
27-05-2025
- Business
- Yahoo
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
SAN DIEGO, May 27, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its rare disease portfolio. "We are delighted to welcome Allyson to Acadia," said Catherine Owen Adams, Chief Executive Officer. "She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results. Her leadership across therapeutic areas—including oncology, immunology, CNS, infectious disease, cardiovascular and metabolic disorders—as well as her experience specifically in rare oncology, will be invaluable as we grow the DAYBUE brand and advance our pipeline to bring new therapies to patients in need." Allyson's distinguished career spans more than 20 years in the global pharmaceutical industry including various sales positions, both in primary care and specialty sectors, at Pfizer, and significant commercial roles at Bristol Myers Squibb (BMS). Most recently, Allyson served as Senior Vice President and Business Unit Head, U.S. Oncology at BMS, where she provided strategic oversight for two major acquisitions in rare tumors, resulting in successful product launches and significant market share growth. Beyond her operational expertise, Allyson is recognized as a driven and highly capable leader who fosters an inclusive culture that embraces both strategic and solution-oriented innovation. "I am excited to join Acadia Pharmaceuticals," said Allyson McMillan-Youngblood. "Acadia has a strong commitment to patient care and innovation, and I look forward to working with the team to drive DAYBUE growth and prepare to bring new therapies to patients with rare diseases." Allyson holds a Bachelor of Science in Business Administration from Florida A&M University. She has been consistently recognized for her ability to lead through change and her commitment to improving patient outcomes throughout her career. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. View source version on Contacts Investor Contact: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27-05-2025
- Business
- Business Wire
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE ® and preparing for future product launches as the Company expands its rare disease portfolio. 'We are delighted to welcome Allyson to Acadia,' said Catherine Owen Adams, Chief Executive Officer. 'She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results. Her leadership across therapeutic areas—including oncology, immunology, CNS, infectious disease, cardiovascular and metabolic disorders—as well as her experience specifically in rare oncology, will be invaluable as we grow the DAYBUE brand and advance our pipeline to bring new therapies to patients in need.' Allyson's distinguished career spans more than 20 years in the global pharmaceutical industry including various sales positions, both in primary care and specialty sectors, at Pfizer, and significant commercial roles at Bristol Myers Squibb (BMS). Most recently, Allyson served as Senior Vice President and Business Unit Head, U.S. Oncology at BMS, where she provided strategic oversight for two major acquisitions in rare tumors, resulting in successful product launches and significant market share growth. Beyond her operational expertise, Allyson is recognized as a driven and highly capable leader who fosters an inclusive culture that embraces both strategic and solution-oriented innovation. 'I am excited to join Acadia Pharmaceuticals,' said Allyson McMillan-Youngblood. 'Acadia has a strong commitment to patient care and innovation, and I look forward to working with the team to drive DAYBUE growth and prepare to bring new therapies to patients with rare diseases.' Allyson holds a Bachelor of Science in Business Administration from Florida A&M University. She has been consistently recognized for her ability to lead through change and her commitment to improving patient outcomes throughout her career. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X.
Yahoo
20-05-2025
- Business
- Yahoo
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday
We recently published a list of . In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other Friday's top performers. The stock market finished the trading week in the green territory as investors looked past the series of mixed corporate earnings performance and inflation worries, amid the easing trade tensions between the US and China. The Dow Jones climbed by 0.78 percent, while the S&P 500 and the tech-heavy Nasdaq grew by 0.70 percent and 0.52 percent, respectively. Beyond major indices, 10 companies—predominantly Bitcoin miners and quantum computing firms—registered a strong finish, thanks to fresh corporate developments boosting investor appetite. In this article, we name Friday's 10 top performers and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments. Acadia Pharmaceuticals soared by 26.48 percent on Friday to finish at $22.26 apiece after securing the backing of a US District Court concerning a patent infringement case versus Aurobindo Pharma (NSE:ARBN). The case stemmed from a case filed by ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) against Aurobindo for allegedly infringing claims 4 and 5 of US Patent No. 11,452,721. It is alleged that the latter committed patent infringement of its drug Nuplazid. Additionally, the judge said that Aurobindo failed to prove that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) claims were invalid. The ruling marked a significant milestone for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to protect its intellectual property rights. Overall, ACAD ranks 1st on our list of Friday's top performers. While we acknowledge the potential of ACAD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ACAD but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at .
